Increased Covid Risk For Those on Evusheld: FDA

FDA has added important information to the emergency authorization of AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab) to inform health care providers and individuals about the increased risk for developing Covid-19 when exposed to variants of SARS-CoV-2 that are not neutralized by Evusheld. The agency says detailed neutralization data can be found in the revised authorized Fact Sheet for Healthcare Providers. Health care professionals should inform patients of this risk and advise patients who develop symptoms to get tested for Covid-19. The agency says that Evusheld remains the only option for pre-exposure prophylaxis of Covid-19 and is authorized for use in immunocompromised individuals who may not mount an adequate response to Covid-19 vaccination, and for individuals for whom Covid-19 vaccination is not recommended due to a history of a severe adverse reaction.